Stock Financial Ratios, Dividends, Split History

FNJN / Finjan Holdings, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)81.77
Enterprise Value ($M)40.60
Book Value / Share1.03
Price / Book2.83
NCAV ($M)30.78
NCAV / Share1.11
Price / NCAV2.66
Share Statistics
Common Stock Shares Outstanding 27,707,328
Common Shares Outstanding 27,719,828
Preferred Stock Shares Outstanding 0
Weighted Average Number Of Diluted Shares Outstanding 26,269,727
Weighted Average Number Of Shares Outstanding Basic 25,353,966
Scoring Models
Piotroski F-Score6.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.80
Return on Assets (ROA)1.25
Return on Equity (ROE)25.75
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio5.39
Income Statement (mra) ($M)
Sales Revenue Goods Net50,484,000.00
Operating Income14.41
Net Income22.81
Earnings Per Share Basic And Diluted0.00
Earnings Per Share Basic0.71
Earnings Per Share Diluted0.68
Earnings Per Share Diluted Excluding Temporary Equity Adjustments0.87
Earnings Per Share Basic Excluding Temporary Equity Adjustments0.90
Cash Flow Statement (mra) ($M)
Cash From Operations16.59
Cash from Investing-1.87
Cash from Financing-1.87
Identifiers and Descriptors
Central Index Key (CIK)1366340

Split History

Stock splits are used by Finjan Holdings, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...

Related News Stories

Finjan: Traditional Modeling Doesn't Work On This Unique Value Opportunity

2018-05-09 seekingalpha
Finjan presents a unique opportunity to invest with substantially mitigated downside exposure as a result of a highly unusual disconnect between market pricing and an exceptionally strong financial position. (10-0)

BRIEF-Finjan Files Patent Infringement Complaint Against Check Point USA, Check Point Israel

2018-05-04 reuters

Finjan Holdings' (FNJN) CEO Phil Hartstein on Q1 2018 Results - Earnings Call Transcript

2018-04-06 seekingalpha
Thank you for standing by. This is the conference operator. Welcome to the Finjan Holdings 2018 Shareholder Update Conference Call. As a reminder all participants are in a listen-only mode and the conference is being recorded. After the presentation there'll be an opportunity to ask questions. [Operator Instructions] (11-1)

BRIEF-Finjan Believe Upward Revenue Trend Will Continue For Q1 And Throughout Remainder Of 2018

2018-03-14 reuters
* FINJAN HOLDINGS - BELIEVE UPWARD REVENUE TREND WILL CONTINUE FOR Q1 AND THROUGHOUT REMAINDER OF 2018 Source text for Eikon: Further company coverage: ([email protected]) (5-1)

BRIEF-Finjan Holdings Says Under Settlement With Symantec, Symantec Parties To Obtain License To Co's Patents

2018-03-01 reuters

CUSIP: 31788H303